The development of novel targeted drugs for CLL, including Bruton’s tyrosine kinase inhibitors (BTKi; ibrutinib and acalabrutinib), BCL2 inhibitors (venetoclax), and phosphatidylinositol 3-kinase inhibitors (PI3Ki; idelalisib and duvelisib), has fundamentally changed the CLL therapy landscape (7) and dramatically improves the prognosis of CLL patients in developed countries. The gene discussed is IBTK; the disease is B-cell chronic lymphocytic leukemia.